Display options
Cite
Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014;2:19doi: 10.1186/2051-1426-2-19.
Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B., & Postow, M. A. (2014). Opportunistic infections in patients treated with immunotherapy for cancer. Journal for immunotherapy of cancer, 219. https://doi.org/10.1186/2051-1426-2-19
Kyi, Chrisann, et al. "Opportunistic infections in patients treated with immunotherapy for cancer." Journal for immunotherapy of cancer vol. 2 (2014): 19. doi: https://doi.org/10.1186/2051-1426-2-19
Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014 Jun 18;2:19. doi: 10.1186/2051-1426-2-19. eCollection 2014. PMID: 24991413; PMCID: PMC4079190.
Copy Download .nbib Format: NLM
Share it on

J Immunother Cancer. 2014 Jun 18;2:19. doi: 10.1186/2051-1426-2-19. eCollection 2014.

Opportunistic infections in patients treated with immunotherapy for cancer.

Journal for immunotherapy of cancer

Chrisann Kyi, Matthew D Hellmann, Jedd D Wolchok, Paul B Chapman, Michael A Postow

Affiliations

  1. New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th Street, New York, NY 10065, USA.
  2. Memorial Sloan-Kettering Cancer Center, Melanoma and Immunotherapeutics Oncology Service, 300 East 66th Street, New York, NY 10065, USA.
  3. Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

PMID: 24991413 PMCID: PMC4079190 DOI: 10.1186/2051-1426-2-19

Abstract

Immunomodulatory antibodies that enhance the immune system to fight cancer are revolutionizing the treatment of patients with an expanding variety of malignancies. There is a unique spectrum of side effects associated with immunomodulatory antibodies, termed immune-related adverse events (irAEs), which include colitis and hepatitis among others. The treatment of refractory or severe irAEs can occasionally require significant immunosuppression, involving steroids or tumor necrosis factor-alpha antagonists, placing these patients at risk for infections. We present the first reported case to our knowledge of an opportunistic infection in a patient treated with an immunomodulatory antibody. As the use of immunomodulatory antibodies expands and more patients develop irAEs that require treatment with immunosuppression, recognition of the potential for opportunistic infections in this emerging patient population will be critical. Prospective trials are needed to define the optimal immunosuppressive management of irAEs and determine whether prophylactic antiviral, antibacterial, or antifungal therapies are beneficial in this unique population.

Keywords: Immune-related adverse events (irAEs); Immunotherapy; Ipilimumab; Malignancy; Melanoma; Opportunistic infections

References

  1. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  2. J Clin Oncol. 2013 Dec 1;31(34):4311-8 - PubMed
  3. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  4. N Engl J Med. 2011 Jun 30;364(26):2517-26 - PubMed
  5. J Clin Oncol. 2012 Jul 20;30(21):2691-7 - PubMed
  6. N Engl J Med. 2013 Jul 11;369(2):134-44 - PubMed
  7. J Clin Oncol. 2014 Apr 1;32(10):1020-30 - PubMed
  8. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238 - PubMed

Publication Types

Grant support